ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 394

Remission After One Year in ACPA Positive and ACPA Negative Patients with Early Arthritis

K.V.C. Wevers-de Boer1, L. Heimans1, K. Visser1, A.A. Schouffoer2, T.H.E. Molenaar3, J.B. Harbers4, C. Bijkerk5, I. Speyer6, M. de Buck7, P.B. de Sonnaville8, B.A. Grillet9, Tom Huizinga1 and C.F. Allaart1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Haga Hospital, The Hague, Netherlands, 3Dept of Rheumatology, Groene Hart Hospital, Gouda, Netherlands, 4Franciscus Hospital, Roosendaal, 5Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, 6Rheumatology, Bronovo Hospital, Den Haag, Netherlands, 7MCH, The Hague, 8Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, 9Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-CCP antibodies, remission and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects I: Drug Studies/Drug Safety/Drug Utilization/Disease Activity & Remission

Session Type: Abstract Submissions (ACR)

Background/Purpose: To evaluate possible differences in clinical response after one year of remission steered treatment in Anti Citrullinated Protein Antibody (ACPA) positive and negative RA and UA patients in the IMPROVED study.  

Methods: IMPROVED is a multicenter trial in 479 rheumatoid arthritis (RA, 2010 criteria, symptoms <2 years) and 122 undifferentiated arthritis (UA) patients with a baseline Disease Activity Score (DAS) ≥1.6. All patients started with methotrexate (MTX) and a tapered high dose of prednisone. Patients in early remission (DAS<1.6 at t=4 months) tapered prednisone to zero and when still in remission at t=8 months, also tapered MTX to zero. Patients not in early remission were randomized to a combination of MTX, hydroxychloroquine (HCQ), sulphasalazine (SSZ) and low dose prednisone (arm 1) or to adalimumab (ADA) with MTX (arm 2). If not in remission at t=8 months, arm 1 switched to ADA+MTX and arm 2 increased ADA. Proportions remission after one year were compared between ACPApos and ACPAneg UA and RA patients.

Results: Of the UA patients, 111 (91%) were ACPApos and 4 (3%) ACPAneg (data not shown), of the RA patients 324 (68%) were ACPApos and 148 (31%) ACPAneg. Twenty-three patients had missing data. ACPAneg UA patients had a lower baseline DAS compared to ACPAneg and ACPApos RA. Both ACPAneg RA and UA patients had a shorter symptom duration than ACPApos RA patients (table). Early remission was achieved less often in ACPAneg RA patients compared to ACPAneg UA and ACPApos RA patients. After 1 year, similar proportions in ACPApos and ACPAneg RA and UA patients achieved remission. Patients in early remission most often were in remission after one year regardless of ACPA status or classification. ACPApos patients in arm 2 more often achieved remission after 1 year than ACPApos patients in arm 1 (18 (51%) vs 10 (25%), p=0.01). A similar trend was seen for ACPAneg patients (table). Independent predictors for achieving remission after 1 year are male sex, low baseline DAS and achieving early remission. ACPA status was not predictive for remission after one year.

Conclusion: In the IMPROVED trial remission after 1 year is achieved in similar proportions of patients with early arthritis, regardless of ACPA status or classification. A low baseline DAS and achieving early remission after initial treatment with prednisone and methotrexate is predictive for achieving remission after one year. Of those not achieving early remission, ACPApos RA, and probably ACPAneg UA and RA patients, benefit more from a treatment strategy with adalimumab than of one with multiple DMARDs with low dose prednisone.

Table: Baseline characteristics and proportions remission after one year of ACPA positive and negative UA and RA patients.

UA(APCAneg)

n=111

RA(ACPApos)

n=324

RA(ACPAneg)

n=148

P-value

Baseline DAS (mean, SD)

2.7 (0.6)

3.2 (0.9)

3.6 (0.9)

<0.001

Baseline HAQ (mean, SD)

1.0 (0.6)

1.1 (0.7)

1.3 (0.7)

0.004

Age, years (mean, SD)

51 (16)

51 (13)

53 (15)

0.7

Sympt dur., weeks (median, IQR)

16 (8-29)

20 (9-37)

14 (9-27)

0.09

Female no (%)

68 (61)

227 (70)

99 (67)

0.2

Early remission no (%)

69 (62)

213 (66)

75 (51)

0.006

Remission after 1 year

Total study group no (%)

64 (58)

176 (54)

76 (51)

0.3

Early remission group no (%)

48 (70)

141 (66)

56 (75)

0.2

Arm 1 no (%)

6/17 (35)

10/40 (25)

5/26 (19)

0.4

Arm 2 no (%)

5/10 (50)

18/36 (51)

9/27 (33)

0.2


Disclosure:

K. V. C. Wevers-de Boer,
None;

L. Heimans,
None;

K. Visser,
None;

A. A. Schouffoer,
None;

T. H. E. Molenaar,
None;

J. B. Harbers,
None;

C. Bijkerk,
None;

I. Speyer,
None;

M. de Buck,
None;

P. B. de Sonnaville,
None;

B. A. Grillet,
None;

T. Huizinga,
None;

C. F. Allaart,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/remission-after-one-year-in-acpa-positive-and-acpa-negative-patients-with-early-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology